ICE Bioscience
Tongzhou
About ICE Bioscience
ICE Bioscience is an Innovative CRO+ Explorer company focusing in early drug discovery services from target validation to pre-clinical candidate identification, with strong capabilities and technologies in Immunology and Oncology, Cardiovascular and CNS diseases areas. ICE Bioscience provides high professional communication and flexible collaboration models, to speed up drug discovery process better and faster. ICE Bioscience has wide target-based panel screening platform ready-to-use, we keep trying to expand diverse techniques related to Biology and Pharmacology, to support various drug discovery purpose for different indications and clinical needs, we do have quite a lot of new assays development experience and passion, to accomplish target identification and assay validation, compounds screening from hit to lead, to pre-clinical drug candidate selection.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $27.9M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2024)
- Website: ice-biosci.com
- Phone: 010 - 67809840
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/ice-bioscience-8872 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.